Atrium commits $5 million to nutrition research for metabolic syndrome

By Stephen Daniells

- Last updated on GMT

© iStock/rez-art
© iStock/rez-art

Related tags Metabolic syndrome Nutrition

Canada’s Atrium Innovations has announced a multi-million, multi-year research initiative to study the role and potential of nutrition against silent inflammation and metabolic syndrome.

Metabolic syndrome (MetS) is a condition characterised by central obesity, hypertension, and disturbed glucose and insulin metabolism. The syndrome has been linked to increased risks of both type-2 diabetes and cardiovascular disease (CVD).

Fifteen per cent of adult Europeans are estimated to be affected by MetS, while the US statistic is estimated to be a whopping 32 percent. Obesity is established to be the main risk factor for MetS.

Speaking with NutraIngredients-USA, said Dr Barry Ritz, VP of scientific and regulatory affairs for Atrium Innovations explained that metabolic syndrome is an attractive target for nutrition and dietary supplements since all of the characteristics associated with the syndrome are “modifiable by nutrition and lifestyle”​.

“We wanted to have a targeted but flexible program and not a series of isolated studies,” ​explained Dr Ritz, and a condition like metabolic syndrome fits with this.

The potential nutritional interventions also fit with this flexibility, with a focus on extracts from small fruits and polyphenols they contain (going beyond the antioxidant effects), fish oil, probiotics, and systemic enzyme therapy.

The effort – which includes a collaboration with a strategic partner, the Institute of Nutraceuticals and Functional Foods (INAF) at Université Laval – has a projected total spend of over $5 million, including partial support from governmental agencies.

Dr Ritz described INAF as the “premier institution dedicated wholly to the study of dietary supplements”​, for “cutting-edge research on the role of nutritional therapies in managing metabolic syndrome”​.

“INAF has specific scientific expertise and interesting methodologies to study metabolic syndrome and silent inflammation,”​ he said.

Spectrum of products

Barry Ritz
Dr Barry Ritz, Atrium Innovations

“We have always believed in the importance of research. This investment provides further indication of the depth of our commitment,”​ said Pierre Fitzgibbon, President and CEO.

 “Applying a more sophisticated science-based approach to our whole spectrum of products, we have the ability to positively affect the quality of life of people by helping them maintain their health and prevent serious diseases.”

Related news

Show more

Related products

show more

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 22-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

New postbiotic for gut & skin health benefits

New postbiotic for gut & skin health benefits

Content provided by Kerry ProActive Health | 14-May-2024 | Product Presentation

Plenibiotic™ (Lactobacillus casei subsp. casei 327) is a rice-derived postbiotic providing a holistic approach to digestive and skin health. It offers...

Related suppliers

1 comment

They always have it backwards

Posted by Rob Whitelock,

"Obesity is established to be the main risk factor for MetS."

Wrong way about. Obesity is the main SYMPTOM of the underlying metabolic disorder. As long as people keep viewing obesity as a cause, and not a symptom, they will continue to treat the wrong thing.

Report abuse

Follow us

Products

View more

Webinars